Glaucoma

March 14, 2019

Ribonucleic acid-based therapy for glaucoma:  LncRNA SNHG1  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 14/March/2019, 6.58 pm

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, […]
March 12, 2019

Ribonucleic acid-based therapy for glaucoma:  LncRNA TUG1  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 13/March/2018, 5.26 am

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, […]
February 26, 2019

Cholecalciferol-based therapy for glaucoma:  1α, 25 (OH)2D/Cholecalciferol/Calcitriol  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 26/February/2019, 8.50 am

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, […]
February 25, 2019

Lipid-lowering agent Fenofibrate comes to the rescue of glaucoma: Fenofibrate (trade name: Tricor,  Fenacor, Feno-TG, Fenobate, Fenocor, Fenofibric, Fenolip and others), a drug used to lower cholesterol and triglycerides,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 26/February/2019, 12.14 am

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, […]